Tesaro Inc. (TSRO) announced Wednesday morning that its Phase 3 trial of niraparib successfully achieved its primary endpoint of progression-free survival in patients with ovarian cancer.
from RTT - Before the Bell http://ift.tt/29d2NlW
via IFTTT
No comments:
Post a Comment